Antibiotic-resistant organism infection

American Surgeon

Volumn 66, Issue 2, 2000, Pages 112-116

  Postier, Russell G ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; ERYTHROMYCIN; MACROLIDE; QUINOLONE DERIVATIVE; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; CANDIDA; CONFERENCE PAPER; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCUS; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOSIS; SURGICAL INFECTION;

ANTIBIOTIC PROPHYLAXIS; CANDIDIASIS; DRUG RESISTANCE, MICROBIAL; HUMANS; SURGICAL WOUND INFECTION;

EID: 0033957047     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in Clin Infect Dis 1997;25:584-99.
2. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.
3. Cohen FL, Tartasky D. Microbial resistance to drug therapy: A review. Am J Infect Control 1997;25:51-64.
4. File TM Jr. Overview of resistance in the 1990s. Chest 1999;115(3 Suppl):3S-8S.
5. Neu HC. Emerging trends in antimicrobial resistance in surgical infections: A review. Eur J Surg Suppl 1994;573:7-18.
6. Barg N. New resistance mechanisms of common bacterial pathogens. Contemp Intern Med 1995;7:61-69.
7. Shlaes DM, Rice LB. Emerging mechanisms of B-Lactam resistance: An update. Infect Dis Clin Pract 1995;4:S175-S186.
8. Thornsberry C. Trends in antimicrobial resistance among today's bacterial pathogens. Pharmacotherapy 1995;15:3S-8S.
9. Neu HC. The crisis in antibiotic resistance. Science 1992; 257:1064-73.
10. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
11. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
12. Sanders CC, Sanders WE. Resistance to antibacterial agents. In: Jungkind DL, ed. Antimicrobial Resistance: A Crisis in Health Care. NY: Plenum Press, 1995, pp 15-23.
13. Hayes JD, Wolf CR. Molecular mechanisms of drug resistance. Biochem J 1990;272:281-95.
14. Chopra I. Efflux-based antibiotic resistance mechanisms: The evidence for increasing prevalence. J Antimicrob Chemother 1992;30:737-9.
15. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993;37:1563-71.
16. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72: 195-8.
17. Jones RN. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med 1996;100(6A):3S-12S.
18. Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in staphylococci: Epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am 1997;11:813-49.
19. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-6.
20. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus: Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;340:493-501.
21. Nicas TI, Zeckel ML, Braun DK. Beyond vancomycin: New therapies to meet the challenge of glycopeptide resistance. Trends Microbiol 1997;5:240-9.
22. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91(3B):72S-75S.
23. French GL. Enterococci and vancomycin resistance. Clin Infect Dis 1998;27(Suppl 1):S75-83.
24. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991;91(3B):86S-89S.
25. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247-51.
26. Vanden Bossche H, Willemsens G, Marichal P. Anti-Candida drugs: The biochemical basis for their activity. Crit Rev Microbiol 1987;15:57-72.
27. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402.
28. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994;38:1422-7.
29. McGowan JE Jr. Antibiotic resistance in hospital bacteria: Current patterns, modes for appearance or spread, and economic impact. Rev Med Microbiol 1991;2:161-9.
30. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983;5: 1033-48.